The secretion profile of mesenchymal stem cells and potential applications in treating human diseases

Han, Yuyi; Yang, Jianxin; Fang, Jiankai; Zhou, Yipeng; Candi, Eleonora; Wang, Jihong; Hua, Dong; Shao, Changshun; Shi, Yufang

doi:10.1038/s41392-022-00932-0

Cited by 262 publications

(201 citation statements)

References 312 publications

Supporting

Mentioning

141

Contrasting

Order By: Relevance

“…Recently, the secretome profile of MSCs and its potential application in clinical settings have emerged as a new player in the field, with a recently published comprehensive review including MSC-derived exosomes. 451 , 452 To date, the therapeutic potential of MSCs is believed to be strongly influenced by their secretomes, including growth factors, cytokines, chemokines, and exosomes. 453 However, this body of knowledge is also not fully included in our discussion, as this review focuses on the function and potency of MSCs as a whole with considerations derived from published clinical data.…”

Section: Limitations Of the Current Hypothesismentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

405

138

View full text Add to dashboard Cite

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.

show abstract

Section: Limitations Of the Current Hypothesismentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

405

138

View full text Add to dashboard Cite

show abstract

“…In this study, HMSC were used as the control due to its multipotent differentiation capacity into at least three mesodermal lineages including chondrocytes, osteoblasts, and adipocytes [ 43 ]. To date, reports have shown an increasing number of MSC-based clinical trials for diseases associated with wound healing, inflammation, and degeneration in various organs and tissues [ 44 ]. HMSC also have the potential to differentiate into nonmesodermal lineages, specifically neurons and glia [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Combination of Goniothalamin and Sol-Gel-Derived Bioactive Glass 45S5 Enhances Growth Inhibitory Activity via Apoptosis Induction and Cell Cycle Arrest in Breast Cancer Cells MCF-7

Bakar

Ali

Noor

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. Combination of natural products with chemically synthesised biomaterials as cancer therapy has attracted great interest lately. Hence, this study is aimed at investigating the combined effects of goniothalamin and bioactive glass 45S5 (GTN-BG) and evaluating their anticancer properties on human breast cancer cells MCF-7. Methods. The BG 45S5 was prepared using the sol-gel process followed by characterisation using PSA, BET, SEM/EDS, XRD, and FTIR. The effects of GTN-BG on the proliferation of MCF-7 were assessed by MTT, PrestoBlue, and scratch wound assays. The cell cycle analysis, Annexin-FITC assay, and activation of caspase-3/7, caspase-8, and caspase-9 assays were determined to further explore its mechanism of action. Results. The synthesised BG 45S5 was classified as a fine powder, having a rough surface, and contains mesopores of 12.6 nm. EDS analysis revealed that silica and calcium elements are the primary components of BG powders. Both crystalline and amorphous structures were detected with 73% and 27% similarity to Na2Ca2(Si2O7) and hydroxyapatite, respectively. The combination of GTN-BG was more potent than GTN in inhibiting the proliferation of MCF-7 cells. G0/G1 and G2/M phases of the cell cycle were arrested by GTN and GTN-BG. The percentage of viable cells in GTN-BG treatment was significantly lower than that in GTN. In terms of activation of initiator caspases for both extrinsic and intrinsic apoptosis pathways, caspase-8 and caspase-9 were found more effective in response to GTN-BG than GTN. Conclusion. The anticancer effect of GTN in MCF-7 cells was improved when combined with BG. The findings provide significant insight into the mechanism of GTN-BG against MCF-7 cells, which can potentially be used as a novel anticancer therapeutic approach.

show abstract

“…Mesenchymal stem cells (MSCs) are a particularly attractive therapeutic agent for treating CLI. MSCs have outstanding advantages over the other stem cell populations, they can be obtained from healthy allogeneic donors, present low immunogenicity (reduced expression of MHC class II constitutive molecules), have anti-inflammatory properties, and are relatively simple to grow and expand in vitro [ 13 , 14 ]. These characteristics have recently encouraged the development of preclinical and clinical trials for the treatment of ischemic disorders, including stroke, coronary artery disease, and CLI [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cells for critical limb ischemia: their function, mechanism, and therapeutic potential

et al. 2022

View full text Add to dashboard Cite

Peripheral arterial disease is atherosclerotic occlusive disease of the lower extremity arteries and afflicts hundreds of millions of individuals worldwide. Its most severe manifestation is chronic limb-threatening ischemia (Petersen et al. (Science 300(5622):1140–2, 2003)), which is associated with severe pain at rest in the limbs, which progresses to necrosis, limb amputation, and/or death of the patient. Consequently, the care of these patients is considered a financial burden for both patients and health systems. Multidisciplinary endeavors are required to address this refractory disease and to find definitive solutions that lead to improved living conditions. Revascularization is the cornerstone of therapy for preventing limb amputation, and both open vascular surgery and endovascular therapy play a key role in the treatment of patients with CLI. Around one-third of these patients are not candidates for conventional surgical treatment, however, leading to higher amputation rates (approaching 20–25% at one year) with high morbidity and lower quality of life. Advances in regenerative medicine have enabled the development of cell-based therapies that promote the formation of new blood vessels. Particularly, mesenchymal stem cells (MSCs) have emerged as an attractive therapeutic agent in various diseases, including CLI, due to their role in tissue regeneration and immunomodulation. This review discusses the characteristics of MSCs, as well as their regenerative properties and their action mechanisms on CLI.

show abstract

The secretion profile of mesenchymal stem cells and potential applications in treating human diseases

Cited by 262 publications

References 312 publications

Stem cell-based therapy for human diseases

Stem cell-based therapy for human diseases

Combination of Goniothalamin and Sol-Gel-Derived Bioactive Glass 45S5 Enhances Growth Inhibitory Activity via Apoptosis Induction and Cell Cycle Arrest in Breast Cancer Cells MCF-7

Mesenchymal stem cells for critical limb ischemia: their function, mechanism, and therapeutic potential

Contact Info

Product

Resources

About